Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Cutting Edge: IL-6-Dependent Autoimmune Disease: Dendritic Cells as a Sufficient, but Transient, Source.
Month of birth as a risk factor for multiple sclerosis: an update.
Atomic view of a toxic amyloid small oligomer.
Effect of virtual reality-based balance training in multiple sclerosis.
siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line.
Demyelinating disease in SLE: Is it multiple sclerosis or lupus?
B-cell-directed therapy: which B cells should be targeted and how?
Scoring treatment response in patients with relapsing multiple sclerosis.
[Progress of demyelinating animal models in the central nervous system].
Evaluating treatment effect within a multivariate stochastic ordering framework: Nonparametric combination methodology applied to a study on multiple sclerosis.
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.
Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function.
AMPYRA® two-year safety data presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Unilateral ankle dorsiflexor spasticity: an uncommon, disabling complication of transverse myelitis.
FTY720 attenuates excitotoxicity and neuroinflammation.
MENGA: A New Comprehensive Tool for the Integration of Neuroimaging Data and the Allen Human Brain Transcriptome Atlas.
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Closing the clinical-radiological paradox using the visual pathway in multiple sclerosis.
Prevalence and incidence of multiple sclerosis in central Poland, 2010-2014.
Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.
Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4.
A case with neuromyelitis optica mimicking Susac's syndrome.
Pain mechanisms in multiple sclerosis.
Association of Neuromyelitis Optica With Severe and Intractable Pain.
Pages
« first
‹ previous
…
205
206
207
208
209
210
211
212
213
…
next ›
last »